Last reviewed · How we verify
NCT06590155
Erythropoietin in HIE Neonate
EARLY_PHASE1 trial testing Erythropoietin in Neonatal Hypoxic Ischemic Encephalopathy in 3 participants. Not yet recruiting.
24 February 2029
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 3 |
| Start date | 24 November 2024 |
| Primary completion | 24 February 2029 |
| Estimated completion | 24 February 2029 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Erythropoietin — full drug profile →
Conditions studied
- Neonatal Hypoxic Ischemic Encephalopathy — all drugs for Neonatal Hypoxic Ischemic Encephalopathy →
Sponsor
Assiut University
Who can join
Adults 1 Day to 1 Month, any sex, with Neonatal Hypoxic Ischemic Encephalopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
this study is aim to delineate the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy the study is conducted to answer the question : is erythropoietin will improve neonatal hypoxic ischemic encephalopathy?
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06590155
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Erythropoietin
Trials testing the same drug.
- NCT06983756 — " Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Out · not yet recruiting
- NCT06542393 — PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG) · Phase 2 · recruiting
- NCT05395195 — Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial) · Phase 3 · recruiting
- NCT05300477 — Pharmacological Countermeasures for High Altitude · Phase 4 · active not recruiting
- NCT05325073 — Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients · Phase 4 · active not recruiting
Other recruiting trials for Neonatal Hypoxic Ischemic Encephalopathy
Currently open trials in the same condition.
- NCT06747260 — Feasibility and Safety of Intranasally Administered Breast Milk in HIE · EARLY_PHASE1 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06590155 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06590155.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing